Document:

Exhibit 10.1

 

CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [****], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED
INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

 

OEM SUPPLY AND LICENSE AGREEMENT

 

This Manufacturing Supply Agreement, dated as
of August 10, 2016 (the “Agreement”), is entered into by and between
Bio-Techne Corp., a Minnesota corporation having its principal place of business at 614 McKinley
Place NE (“Bio-Techne”), and Olink Proteomics AB, a Swedish company, registration no. 559046-8632,
having an address at Dag Hammarskjölds väg 52B, SE-752 37 Uppsala, Sweden
(“Buyer”, and together with Bio-Techne, the “Parties”, and each, a “Party”).

 

WHEREAS, Bio-Techne is in the business of manufacturing and
selling antibodies, proteins and related reagents for research and diagnostic use;

 

WHEREAS, Buyer wishes to purchase certain Goods (as defined
below) exclusively from Bio- Techne; and WHEREAS, Bio-Techne desires to manufacture and sell the Goods to Buyer.

 

NOW, THEREFORE, in consideration
of the mutual covenants, terms and conditions set forth herein,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree
as follows:

 

1.            
Definitions. Capitalized terms have the meanings set forth or referred to in this Section 1.

 

“Action”
means any claim, action, cause of action, demand, lawsuit,
arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation
of any nature, civil, criminal, administrative, regulatory or other, whether
at law, in equity or otherwise.

 

“Affiliate”
of a Person means any other Person that directly or indirectly, through one or more intermediaries,
Controls, is Controlled by, or is under common Control
with, such Person.

 

“Agreement”
has the meaning set forth in
the preamble to this Agreement.

 

“Basic Purchase Order
Terms” means, collectively, any one or more of the following terms specified by Buyer
in a Purchase Order pursuant to Section 3.2: (a) a list of the Goods to be purchased; (b)
the quantity of each of the Goods ordered; (c) the Requested
Delivery Date; (d) the unit Price for each of the Goods to be purchased; (e) the billing address; and (f) the
Delivery Location. For the avoidance of doubt, the
term “Basic Purchase Order Terms” does not include any general
terms or conditions of any Purchase Order.

 

“Bio-Techne”
has the meaning set forth in the preamble to this Agreement.

 

“Bio-Techne’s
Intellectual Property Rights” means [*****].

 

Bio-Techne’s Trademarks”
means [*****].

 

    1

     

    

 

“Business Day”
means any day except Saturday, Sunday or any other day on which commercial banks located in Minneapolis, MN, USA are authorized
or required by Law to be closed for business.

 

“Buyer” has
the meaning set forth in the preamble to this Agreement.

 

“Buyer Contracts”
means all contracts or agreements to which Buyer is a party or to which any of its material assets are bound.

 

“Buyer Products”
means [*****].

 

“Buyer Services”
means [*****].

 

“Claim” means
any Action brought against a Person entitled to indemnification under Section 10.

 

“Confidential Information”
has the meaning set forth in Section 13.1.

 

“Control”
(and with correlative meanings, the terms “Controlled by” and “under common Control with”) means, with
respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management
or policies of another Person, whether through the ownership or voting securities, by contract, or otherwise.

 

“Defective”
means not conforming to the Product Warranty under Section 10.3.

 

“Defective Goods”
means goods shipped by Bio-Techne to Buyer pursuant to this Agreement that are Defective.

 

“Delivery Location”
means the street address within the Territory for delivery of the Goods specified in the applicable Purchase Order.

 

“Disclosing Party”
has the meaning set forth in Section 13.1.

 

“Dispute”
has the meaning set forth in Section 16.15.

 

“Dispute Notice”
has the meaning set forth in Section 16.15.

 

“Effective Date”
means January 1, 2016.

 

“Force Majeure Event”
has the meaning set forth in Section 16.19.

 

“Forecast”
means, with respect to any [*****] period, a good faith projection or estimate of Buyer’s requirements for Goods during each
[*****] during the period, which approximates, as nearly as possible, based on information available at the time to Buyer, the
quantity of Goods that Buyer may order [*****].

 

“Goods” means
the goods identified on Schedule 1 and described in the Specifications.

 

    2

     

    

 

“Governmental Authority”
means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such
government or political subdivision, or any self-regulated organization or other nongovernmental regulatory authority or quasi-governmental
authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any
arbitrator, court or tribunal of competent jurisdiction.

 

“Governmental Order”
means any order, writ, judgment, injunction, decree, stipulation, award or determination entered by or with any Governmental Authority.

 

“Indemnified Party”
has the meaning set forth in Section 11.1.

 

“Indemnifying Party”
has the meaning set forth in Section 11.1.

 

“Initial Term”
has the meaning set forth in Section 7.1.

 

“Inspection Period”
has the meaning set forth in Section 4.6.

 

“Intellectual Property
Rights” [*****].

 

“Law” means
any statute, law, ordinance, regulation, rule, code, constitution, treaty, common law, Governmental Order or other requirement
or rule of law of any Governmental Authority.

 

“Losses”
has the meaning set forth in Section 11.1.

 

“Net Sales”
[*****].

 

“Nonconforming
Goods” means any goods received by Buyer from Bio-Techne pursuant to a Purchase Order that: (a) do not conform to the
catalog number listed in the applicable Purchase Order; (b) do not fully conform to the Specifications;
or (c) materially exceed the quantity of Goods ordered by Buyer pursuant to this Agreement or any Purchase Order. Where the
context requires, Nonconforming Goods are deemed to be Goods for purposes of this Agreement.

 

“Notice”
has the meaning set forth in Section 16.4.

 

“Party”
has the meaning set forth in the preamble to this Agreement.

 

“Patents”
means all patents (including all reissues, divisional, provisionals, continuations and continuations-in-part, re-examinations,
renewals, substitutions and extensions thereof), patent applications, and other patent rights and any other Governmental Authority-issued
indicia of invention ownership (including inventor’s certificates, petty patents and patent utility models).

 

“Payment
Failure” has the meaning set forth in Section 7.3(a).

 

    3

     

    

 

“Person”
means any individual, partnership, corporation, trust, limited liability entity, unincorporated organization, association, Governmental
Authority or any other entity.

 

“Personnel”
of a Party means any agents, employees, contractors or subcontractors engaged or appointed by such
Party.

 

“Price”
has the meaning set forth in Section 5.1.

 

“Product
Warranty” has the meaning set forth in Section 10.3.

 

“Purchase
Order” means Buyer’s purchase order issued to Bio-Techne hereunder, including all terms and conditions attached
to, or incorporated into, such purchase order.

 

“Receiving
Party” has the meaning set forth in Section 13.1.

 

“Renewal
Term” has the meaning set forth in Section 7.2.

 

“Representatives”
means a Party’s Affiliates and each of their respective Personnel, officers, directors,
partners, shareholders, attorneys, third-party advisors, successors and permitted assigns.

 

“Requested Delivery
Date” means the requested delivery date for Goods ordered hereunder that is set forth
in a Purchase Order, which must be a Business Day no less than [*****] following delivery of
the applicable Purchase Order to Bio-Techne.

 

“Specifications”
means the specifications for the Goods attached hereto as Exhibit A and Exhibit B.

 

“Taxes”
means any and all present and future sales, income, stamp and other taxes, levies, imposts, duties, deductions, charges, fees or
withholdings imposed, levied, withheld or assessed by any Governmental Authority, together
with any interest or penalties imposed thereon.

 

“Term”
has the meaning set forth in Section 7.2.

 

“Trademarks”
means all rights in and to US and foreign trademarks, service marks, trade dress, trade names, brand names, logos, corporate names
and domain names and other similar designations of source, sponsorship, association or origin, together with the goodwill symbolized
by any of the foregoing, in each case whether registered or unregistered and including all registrations and applications for,
and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection in any part of the world.

 

“Trade
Secrets” [*****].

 

“US”
means the United States of America.

 

“Warranty
Period” has the meaning set forth in Section 10.3.

 

    4

     

    

 

2.           
 Purchase and Sale of Goods.

 

2.1          
Purchase and Sale. 

 

2.1.1       
Subject to the terms and conditions of this Agreement, during the Term, Buyer shall [*****], and Bio-Techne shall
manufacture and sell to Buyer, [*****].

 

2.1.2       
Unless otherwise provided in Schedule 1, subject to the terms and conditions of this Agreement, Buyer shall purchase
from Bio-Techne, and Bio-Techne shall manufacture and sell to Buyer, [*****] the Goods; provided, that, notwithstanding anything
to the contrary contained herein: (i) [*****].

 

2.2          
Terms of Agreement Prevail Over Buyer’s Purchase Order. The Parties intend for the express terms and
conditions contained in this Agreement (including any Schedules and Exhibits hereto) and the Basic Purchase Order Terms contained
in the applicable Purchase Order to exclusively govern and control each of the Parties’ respective rights and obligations
regarding the subject matter of this Agreement, and this Agreement is expressly limited to such terms and conditions. Without limitation
of the foregoing, any additional, contrary or different terms contained in any Purchase Order or other request or communication
by Buyer pertaining to the sale of Goods by Bio-Techne, and any attempt to modify, supersede, supplement or otherwise alter this
Agreement, will not modify this Agreement or be binding on the Parties unless such terms have been fully approved in a signed writing
by authorized Representatives of both Parties.

 

2.3        
Right to Manufacture and Sell Competitive Goods. This Agreement does not limit Bio-Techne’s right to
manufacture or sell, or preclude Bio-Techne from manufacturing or selling, to any Person, or entering into any agreement with any
other Person related to the manufacture or sale of, the Goods and other goods or products that are similar to or competitive with
the Goods.

 

2.4         
Use of Goods and Restrictions. The Goods may be repackaged and relabeled, and must be sold or used under Buyer’s
own label; Bio-Techne shall not be identified on any Product sold by Buyer (e.g., packaging, printed marketing materials, web,
etc.), provided, however, that Buyer may inform its customers of the identity of Bio-Techne if asked directly about Buyer’s
suppliers. Buyer acknowledges that Goods are not submitted by Bio-Techne for regulatory review or validated for clinical, therapeutic
or diagnostic use, safety or efficacy, or any other specific use or application. It is solely Buyer’s responsibility to ensure
the Goods are suitable for Buyer’s intended market. Buyer is solely responsible for complying with all applicable laws, regulations
and governmental policies when reselling Goods and for obtaining all necessary approvals, permissions and/or licenses or intellectual
property rights from applicable third parties, as may be required for Buyer’s intended uses or sales. Buyer is also responsible
for any technical support provided to its customers.

 

    5

     

    

 

3.            
Ordering Procedure.

 

3.1         
 Non-binding Forecasts of Buyer’s Requirements. Within [*****] following the full execution of this
Agreement, Buyer shall provide to Bio-Techne a Forecast for the [*****]. Pursuant to Bio-Techne’s reasonable request, but
in no case more frequently than [*****], Buyer shall deliver to Bio-Techne a [*****] Forecast for the period beginning with the
first day of such [*****]. Forecasts are for informational purposes only and do not create any binding obligations on behalf of
either Party; provided, however, that Bio-Techne shall not be required to manufacture and sell to Buyer any quantity of Goods that
is unreasonably disproportionate to any Forecast for the [*****] covered by such Forecast. Upon receipt of each Forecast, Bio-Techne
shall provide written notification to Buyer of any deviations or changes to the Goods or Specifications.

 

3.2         
Purchase Orders. Buyer shall issue to Bio-Techne Purchase Orders (containing applicable Basic Purchase Order
Terms that are consistent with the terms of this Agreement), in written form via facsimile, e-mail or US mail. By issuing a Purchase
Order to Bio-Techne, Buyer makes an offer to purchase Goods pursuant to the terms and conditions of this Agreement and the Basic
Purchase Order Terms contained in such Purchase Order, and on no other terms. For the avoidance of doubt, any variations made to
the terms and conditions of this Agreement by Buyer in any Purchase Order are void and have no effect. Buyer shall be obligated
to purchase from Bio-Techne quantities of Goods specified in a Purchase Order.

 

3.3         
Acceptance, Rejection and Cancellation of Purchase Orders. Bio-Techne accepts a Purchase Order by confirming
the order in writing or by delivering the applicable Goods to Buyer, whichever occurs first. Bio-Techne may reject a Purchase Order
or cancel a previously accepted Purchase Order, which it may do without liability or penalty, and without constituting a waiver
of any of Bio-Techne’s rights or remedies under this Agreement or any Purchase Order, by providing written notice to Buyer
specifying the applicable date of rejection or cancellation, if any one or more of the events described under Sections 7.3(a)-(c)
has occurred.

 

4.            
Shipment, Delivery, Acceptance and Inspection.

 

4.1         
Shipment. Unless otherwise expressly agreed by the Parties in writing, Bio- Techne shall select the method
of shipment of and the carrier for the Goods. Bio-Techne may, in its sole discretion, without liability or penalty, make partial
shipments of Goods to Buyer. Each shipment will constitute a separate sale and Buyer shall pay for the Goods shipped, in accordance
with the payment terms specified in Section 5.3, whether such shipment is in whole or partial fulfillment of a Purchase Order.

 

4.2         
Packaging and Labeling. Bio-Techne shall properly pack, mark and ship Goods and provide Buyer with shipment
documentation showing the Purchase Order number, Bio- Techne’s identification number for the subject Goods, the quantity
of pieces in shipment, the number of cartons or containers in shipment, Bio-Techne’s name, the bill of lading number and
the country of origin.

 

    6

     

    

 

4.3          Delivery. Unless otherwise expressly agreed by the Parties in writing, Bio-Techne shall deliver the Goods
to the Delivery Location, using Bio-Techne’s standard methods for packaging and shipping such Goods. All Prices are [*****].

 

4.4         
Late Delivery. Any time quoted for delivery is an estimate only; provided, however, that Bio-Techne shall
use commercially reasonable efforts to deliver all Goods on or before the Requested Delivery Date. If Bio-Techne has delayed shipment
of all or any Goods for more than thirty (30) days after the Requested Delivery Date and if such delay is not due to any action
or inaction of Buyer or otherwise excused in accordance with the terms and conditions of this Agreement, Buyer may, as its sole
remedy therefor, cancel the portion of the related Purchase Order covering the delayed Goods by giving Bio-Techne written Notice
within [*****] of the Requested Delivery Date. Buyer has the right to obtain the quantity of Goods covered by the cancelled portion
of such Purchase Order from sources other than Bio-Techne, and all such Goods shall be deemed to have been purchased under this
Agreement for purposes of satisfying Buyer’s purchasing requirements hereunder. Subject to Buyer’s rights under this
Section 4.4, no delay in the shipment or delivery of any Good relieves Buyer of its obligations under this Agreement, including
accepting delivery of any remaining installment or other orders of Goods.

 

4.5         
Transfer of Title and Risk of Loss.

 

(a)              
Title to Goods shipped under any Purchase Order passes to Buyer upon Bio-Techne’s tender of the Goods to the
earner at [*****].

 

(b)              
Risk of loss to Goods shipped under any Purchase Order passes to Buyer upon Bio-Techne’s tender of such units
to the carrier at [*****].

 

4.6         
Inspection. Buyer shall inspect Goods received under this Agreement within [*****] of receipt of such Goods
(“Inspection Period”) and either accept or, only if any such Goods are Nonconforming Goods, reject such Goods.
Buyer will be deemed to have accepted Goods unless it provides Bio-Techne with written Notice of any Nonconforming Goods within
[*****] following the Inspection Period, stating with specificity all defects and nonconformities, and furnishing such other written
evidence or other documentation as may be reasonably required by Bio-Techne (including the subject Goods, or a representative sample
thereof, which Buyer contends are Nonconforming Goods). All defects and nonconformities that are not so specified will be deemed
waived by Buyer, such Goods shall be deemed to have been accepted by Buyer, and no attempted revocation of acceptance will be effective.
If Buyer timely notifies Bio-Techne of any Nonconforming Goods, Bio-Techne shall determine, in its reasonable discretion, whether
the Goods are Nonconforming Goods. If Bio- Techne determines that such Goods are Nonconforming Goods, Bio-Techne shall provide
the remedies set forth in Section 10.5.

 

4.7          
Limited Right of Return. Except as provided under Section 4.6, Section 10.5 and Section 10.7, Buyer has no
right to return Goods shipped to Buyer pursuant to this Agreement.

 

    7

     

    

 

5.            
 Price and Payment.

 

5.1          
Price. Buyer shall purchase the Goods from Bio-Techne at the amounts set forth on Schedule 1 attached hereto
(“Price”). The Price shall remain firm for [*****] after the Effective Date, except as otherwise may be agreed
to in writing by both Parties. Thereafter, upon [*****] prior written notice and no more often than once each year, the Bio- Techne
may adjust the purchase prices by submitting a new Schedule 1 to Buyer; provided however, that such purchase price adjustments
shall be limited to the lesser of [*****] or the percentage increase, if any, in the United States Bureau of Labor Statistics Consumer
Price Index, based on the last published index number. The base index shall be [*****]. The Goods and purchase prices in Schedule
1, as amended from time to time, shall apply to each single purchase order for each single shipment.

 

5.2         
Shipping Charges, Insurance and Faxes. Buyer shall pay for all shipping charges and insurance costs. In addition,
all Prices are exclusive of, and Buyer is solely responsible for, and shall pay all Taxes, with respect to, or measured by, the
manufacture, sale, shipment, use or Price of the Goods (including interest and penalties thereon); provided, however, that Buyer
shall not be responsible for any Taxes imposed on, or with respect to, Bio-Techne’s income, revenues, gross receipts, Personnel
or real or personal property or other assets.

 

5.3         
Payment Terms. Bio-Techne shall issue invoices to Buyer for all Goods ordered, setting forth in reasonable
detail the amounts payable by Buyer under this Agreement. Buyer shall pay to Bio-Techne all invoiced amounts within [*****] from
Buyer’s receipt of such invoice. Buyer shall make all payments in US dollars by check or wire transfer, in accordance with
the following wire instructions:

 

[*****]

 

5.4         
Late Payments. Except for invoiced payments that Buyer has successfully disputed, Buyer shall pay interest
on all late payments (whether during the Term or after the expiration or earlier termination of the Term), calculated daily and
compounded [*****]. Buyer shall also reimburse Bio-Techne for all reasonable costs incurred by Bio-Techne in collecting any late
payments, including attorneys’ fees and court costs. In addition to all other remedies available under this Agreement or
at Law (which Bio-Techne does not waive by the exercise of any rights under this Agreement), if Buyer fails to pay any undisputed
amounts when due under this Agreement, Bio-Techne may (a) suspend the delivery of any Goods, (b) reject Buyer’s Purchase
Orders or cancel accepted Purchase Orders pursuant to the terms of Section 3.3 or (c) terminate this Agreement pursuant to the
terms of Section 7.3(a).

 

5.5           No
Set-off Right. Buyer shall not, and acknowledges that it will have no right, under this Agreement, any Purchase Order,
any other agreement, document or Law to, withhold, offset, recoup or debit any amounts owed (or to become due and owing) to
Bio- Techne or any of its Affiliates, whether under this Agreement or otherwise, against any other amount owed (or to become
due and owing) to it by Bio-Techne or Bio-Techne’s Affiliates, whether relating to Bio-Techne’s or its
Affiliates’ breach or non-performance of this Agreement, any Purchase Order, any other agreement between
(a) Buyer or any of its Affiliates and (b) Bio-Techne or any of its Affiliates, or otherwise.

 

    8

     

    

 

6.           
Royalties.

 

6.1         
Royalties for Buyer Products. Beginning with [*****], Buyer shall pay Supplier a royalty of [*****] of the
Net Sales of any Buyer Products.

 

6.2          
Royalties for Services. Beginning with the [*****], Buyer will pay a royalty of [*****] on the Net Sales for
such Buyer Services.

 

6.3          
[*****].

 

6.4          
Royalty Payments, Reports. Within [*****] after the end of each [*****] in which this Agreement is in effect,
Buyer shall deliver to Bio-Techne full, true, and accurate reports of its activities relating to this Agreement during the preceding
[*****] (hereinafter a “Royalty Report”). These Royalty Reports must include: [*****]. The Royalty Report shall
also separately include the same information for any Buyer’s Services sold or distributed by Buyer. If no royalties are due,
Buyer shall so report.

 

7.           
Term; Termination.

 

7.1         
Initial Term. The term of this Agreement commences on the Effective Date and continues through December 31,
2026, unless it is earlier terminated pursuant to the terms of this Agreement or applicable Law (the “Initial Term”).

 

7.2          
Renewal Term. Upon expiration of the Initial Term, the term of this Agreement will automatically renew for
additional successive five (5) year terms, unless either Party provides written Notice of non-renewal at least one (1) year prior
to the end of the then-current term (each, a “Renewal Term” and together with the Initial Term, the “Term”),
unless any Renewal Term is earlier terminated pursuant to the terms of this Agreement or applicable
Law. If the Initial Term or any Renewal Term is renewed for any Renewal Term(s) pursuant to this Section 7.2, the terms and conditions
of this Agreement during each such Renewal Term will be the same as the terms in effect immediately prior to such renewal. In the
event either Party provides timely Notice of its intent not to renew this Agreement, then, unless earlier terminated in accordance
with its terms, this Agreement terminates on the expiration of the Initial Term or then-current Renewal Term, as applicable.

 

7.3          
Bio-Techne’s Right to Terminate. Bio-Techne may terminate this Agreement, by providing written Notice
to Buyer:

 

(a)              
if Buyer fails to pay any amount when due under this Agreement (“Payment Failure”);

 

(b)               if Buyer
is in material breach of any representation, warranty or covenant of Buyer under this
Agreement (other than committing a Payment Failure), and either the breach cannot be cured or, if the breach can be
cured, it is not cured by Buyer within a commercially reasonable period of time (in no case exceeding [*****] after
Buyer’s receipt of written Notice of such breach;

 

    9

     

    

  

(c)               
if Buyer (i) becomes insolvent or is generally unable to pay, or fails to pay, its debts as they become due, (ii)
files or has filed against it, a petition for voluntary or involuntary bankruptcy or otherwise becomes subject, voluntarily or
involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency Law, (iii)
makes or seeks to make a general assignment for the benefit of its creditors, or (iv) applies for or has appointed a receiver,
trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material
portion of its property or business.

 

Any termination under this Section 7.3 will
be effective on Buyer’s receipt of Bio- Techne’s written Notice of termination or such later date (if any) set forth
in such Notice.

 

7.4          
Buyer’s Right to Terminate. Buyer may terminate this Agreement, by providing written Notice to Bio-Techne:

 

(a)               if Bio-Techne is in material breach of any representation, warranty or covenant of Bio-Techne
under this Agreement and either the breach cannot be cured or, if the breach can be cured,
it is not cured by Bio-Techne within [*****] after Bio- Techne’s receipt of written Notice
of such breach; or

 

(b)              
if Bio-Techne (i) becomes insolvent or is generally unable to pay, or fails to pay,
its debts as they become due, (ii) files or has filed against it, a petition for voluntary or involuntary bankruptcy or otherwise
becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency Law, (iii)
makes or seeks to make a general assignment for the benefit of its creditors, or (iv) applies for or has appointed a receiver,
trustee, custodian or similar agent appointed by order of any
court of competent jurisdiction to take charge of or sell any material portion of its property
or business; or

 

(c)              
in the event of a Force Majeure Event affecting Bio-Techne’s performance under
this Agreement for more than [*****].

 

7.5          
Effect of Expiration or Termination.

 

(a)              
Upon the expiration or earlier termination of this Agreement, all indebtedness of Buyer
to Bio-Techne under this Agreement of any kind, shall become immediately due and payable to Bio-Techne, without further notice
to Buyer.

 

(b)             
Expiration or termination of the Term will not affect any rights or obligations of the
Parties that:

 

(i)                
come into effect prior to termination or expiration of this Agreement; or

 

    10

     

    

 

 

 

 

(ii)             
 otherwise survive the expiration or earlier termination of this Agreement pursuant
to Section 16.3 and were incurred by the Parties prior to such expiration or earlier termination.

 

(c)               
Any Notice of termination under this Agreement automatically operates as a cancellation
of any deliveries of Goods to Buyer that are scheduled to be made subsequent to the effective
date of termination, whether or not any orders for such Goods had been accepted by Bio-Techne. With respect to any Goods that are
still in transit upon termination of this Agreement, Bio-Techne may require, in its sole discretion, that all sales and deliveries
of such Goods be made on either a cash-only or certified-check basis.

 

(d)               
Upon the expiration or earlier termination of this
Agreement, Buyer shall:

 

(i)              
destroy all documents and tangible materials (and any copies) containing, reflecting,
incorporating or based on Bio-Techne’s Confidential Information;

 

(ii)             
permanently erase all of Bio-Techne’s Confidential Information from its computer
systems, except for copies that are maintained as archive copies on its disaster recovery and/or information technology backup
systems. Buyer shall destroy any such copies upon the normal expiration of its backup files; and

 

(iii)           
certify in writing to Bio-Techne that it
has complied with the requirements of this clause.

 

(e)               
Termination of this Agreement will not constitute a waiver of any of either Party’s
rights, remedies or defenses under this Agreement, at law, in equity or otherwise.

 

8.             
Obligations of Buyer.

 

8.1             
Certain Prohibited Acts. Notwithstanding anything to the contrary in this Agreement, neither Buyer nor any
Buyer Personnel shall:

 

(a)               
make any representations, warranties, guarantees, indemnities, similar claims or other commitments:

 

(i)              
actually, apparently or ostensibly on behalf of Bio-Techne, or

 

(ii)             
to any customer or other Person with respect to the Goods, which are additional to or
inconsistent with any then-existing representations, warranties, guarantees, indemnities, similar claims or other commitments
in this Agreement or any written documentation provided by Bio-Techne to Buyer.

 

    11

     

    

 

9.             
Compliance with Laws. Buyer shall at all times comply with all Laws applicable to this Agreement, Buyer’s
performance of its obligations hereunder and Buyer’s use or sale of the Goods. Without limiting the generality of the foregoing,
Buyer shall (a) at its own expense, maintain all certifications, credentials, licenses and permits necessary to conduct its business
relating to the purchase, use or resale of the Goods and (b) not engage in any activity or transaction involving the Goods, by
way of resale, lease, shipment, use or otherwise, that violates any Law.

 

10.           
Representations and Warranties.

 

10.1         
Buyer’s Representations and Warranties. Buyer represents and warrants to Bio- Techne that:

 

(a)                    
it is a corporation, duly organized, validly existing and in good standing under the laws of the Sweden;

 

(b)                    
it is duly qualified to do business and is in good standing in every jurisdiction in which such qualification is
required;

 

(c)                    
it has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder;

 

(d)                    
the execution of this Agreement by its Representative whose signature is set forth at the end of this Agreement,
and the delivery of this Agreement by Buyer, have been duly authorized by all necessary action on the part of Buyer;

 

(e)                    
the execution, delivery and performance of this Agreement by Buyer will not violate, conflict with, require consent
under or result in any breach or default under (i) any of Buyer’s organizational documents, (ii) any applicable Law or (iii)
with or without notice or lapse of time or both, the provisions of any material Buyer Contract;

 

(f)                     
this Agreement has been executed and delivered by Buyer and (assuming due authorization, execution and delivery by
Bio-Techne) constitutes the legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms;

 

(g)                    
it is in compliance with all applicable Laws and Buyer Contracts relating to this Agreement, the Goods and the operation
of its business;

 

(h)                    
it has obtained all licenses, authorizations, approvals, consents or permits required by applicable Laws to conduct
its business generally and to perform its obligations under this Agreement.

 

    12

     

    

 

10.2     
Bio-Techne’s Representations and Warranties. Bio-Techne represents and warrants to Buyer that:

 

(a)                    
 it is a corporation, duly organized, validly existing and in good standing under the laws of the Minnesota;

 

(b)                    
it is duly qualified to do business and is in good standing in every jurisdiction in which such qualification is
required;

 

(c)                    
it has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder;

 

(d)                    
the execution of this Agreement by its Representative whose signature is set forth at the end of this Agreement,
and the delivery of this Agreement by Bio-Techne, have been duly authorized by all necessary action on the part of Bio-Techne;
and

 

(e)                    
the execution, delivery and performance of this Agreement by Bio-Techne will not violate, conflict with, require
consent under or result in any breach or default under (i) any of Bio-Techne’s organizational documents, (ii) any applicable
Law or (iii) with or without notice or lapse of time or both, the provisions of any Bio-Techne Contract;

 

(f)                     
this Agreement has been executed and delivered by Bio-Techne and (assuming due authorization, execution and delivery
by Buyer) constitutes the legal, valid and binding obligation of Bio-Techne, enforceable against Bio-Techne in accordance with
its terms;

 

(g)                    
it is in compliance with all applicable Laws and Bio-Techne Contracts relating to this Agreement, the Goods and the
operation of its business; and

 

(h)                    
it has obtained all licenses, authorizations, approvals, consents or permits required by applicable Laws to conduct
its business generally and to perform its obligations under this Agreement.

 

10.3     
Limited Product Warranty. Subject to the provisions of Sections 10.4 through 10.7, Bio-Techne warrants to
Buyer (the “Product Warranty”) that:

 

(a)                    
for the period of time stated on each Good’s data sheet (the “Warranty Period”), each Good
will materially conform to the specifications set forth on the product data sheet; and

 

(b)                    
Buyer will receive good and valid title to all Goods, free and clear of all encumbrances
and liens of any kind.

 

10.4         
Product Warranty Limitations. The Product Warranty does not apply to any Good that:

 

(a)                    
has been subjected to abuse, misuse, neglect, negligence, accident, improper testing, improper installation, improper
storage, improper handling,

 

abnormal physical stress, abnormal environmental conditions
or use contrary to any instructions issued by Bio-Techne;

 

    13

     

    

 

(b)                    
has been reconstructed, repaired or altered by Persons other than Bio- Techne or its authorized Representative; or

 

(c)                    
has been used with any third-party products, hardware or product that has not been previously approved in writing
by Bio-Techne.

 

10.5         
Buyer’s Exclusive Remedy for Defective Goods or Nonconforming Goods. Notwithstanding any other provision
of this Agreement (except for Section 10.7), this Section 10.5 contains Buyer’s exclusive
remedy for Defective Goods or Nonconforming Goods. Buyer’s remedy under this Section 10.5 is conditioned upon Buyer’s
compliance with its obligations under Section 10.5(a) and Section 10.5(b) below. During the Warranty Period, with respect to any
allegedly Defective Goods:

 

(a)                    
Buyer shall notify Bio-Techne, in writing, of any alleged claim or
defect within [*****] from the date Buyer discovers, or upon reasonable inspection should have discovered, such alleged
claim or defect (but in any event before the expiration of the applicable Warranty Period);

 

(b)                    
Buyer shall ship, at its expense, such allegedly Defective Goods to Bio-Techne’s facility located at Minneapolis,
for inspection and testing by Bio-Techne;

 

(c)                    
if Bio-Techne’s inspection and testing reveals, to Bio-Techne’s reasonable satisfaction, that such Goods
are Defective or Nonconforming and any such defect has not been caused or contributed to by any of the factors described under
Section 10.4 above, subject to Section 10.5(a) and Section 10.5(b). Bio-Techne shall in its sole discretion and at its expense,
repair or replace such Defective Goods; and

 

(d)                    
Bio-Techne shall ship to Buyer, at Bio-Techne’s expense and risk of loss, the repaired or
replaced Goods to a location designated by Buyer, and credit
Buyer for the shipping expense incurred in this Section 10.5(b).

 

Buyer has no right to return for repair, replacement,
credit or refund any Good except as set forth in this Section 10.5 (or if otherwise applicable, Section 10.7). In no event shall
Buyer reconstruct, repair, alter or replace any Good, in whole or in part, either itself or by or through any third party.

 

SUBJECT TO SECTION 10.7, THIS SECTION 10.5
SETS FORTH BUYER’S SOLE REMEDY AND BIO-TECHNE’S ENTIRE LIABILITY FOR ANY BREACH OF THE LIMITED PRODUCT WARRANTY SET
FORTH IN SECTION 10.3.

 

    14

     

    

 

10.6          DISCLAIMER
OF OTHER REPRESENTATIONS AND WARRANTIES; NON-RELIANCE. EXCEPT FOR THE PRODUCT WARRANTY SET FORTH IN SECTION 10.3, (A)
NEITHER BIO-TECHNE NOR ANY PERSON ON BIO-TECHNE’S BEHALF HAS MADE OR MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR
WARRANTY WHATSOEVER, EITHER ORAL OR WRITTEN, INCLUDING ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
TITLE, OR NON-INFRINGEMENT, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE,
ALL OF WHICH ARE EXPRESSLY DISCLAIMED, AND (B) BUYER ACKNOWLEDGES THAT IT HAS NOT RELIED UPON ANY REPRESENTATION OR WARRANTY
MADE BY BIO-TECHNE, OR ANY OTHER PERSON ON BIO-TECHNE’S BEHALF, EXCEPT AS SPECIFICALLY PROVIDED IN SECTIONS 10.2 AND
10.3 OF THIS AGREEMENT.

 

10.7         
Withdrawal of Goods. If Bio-Techne determines that any Goods sold to Buyer may be Defective, at Bio-Techne’s
request, Buyer shall withdraw all similar Goods from sale and, at Bio-Techne’s option, either return such Goods to Bio-Techne
(pursuant to the terms of Section 10.5(b)) or destroy the Goods and provide Bio-Techne with written certification of such destruction.
Notwithstanding the limitations of Section 10.5, if Buyer returns all withdrawn Goods or destroys all withdrawn Goods and provides
Bio-Techne with written certification of such destruction within [*****] following Bio-Techne’s withdrawal request, in either
case consistent with Bio-Techne’s instructions, unless any such defect has not been caused or contributed to by any of the
factors described under Section 10.4, Bio-Techne shall (a) repair or replace all such returned Goods or (b) replace such destroyed
Goods, in either case pursuant to the terms of Section 10.5(d). THIS SECTION 10.7 SETS FORTH BUYER’S SOLE REMEDY AND BIO-TECHNE’S
ENTIRE LIABILITY FOR ANY GOODS THAT ARE WITHDRAWN PURSUANT TO THIS SECTION 10.7.

 

10.8         
Nothing in this Agreement shall be construed as:

 

(a)              
a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in
this Agreement is or will be free from infringement of patents or other intellectual property rights; or

 

(b)              
an obligation to bring or prosecute actions or suits against third parties; or

 

(c)              
conferring by implication, estoppel or otherwise any license or rights under any patents or other intellectual property
of Bio-Techne other than the Goods; or

 

(d)              
an obligation to furnish any know-how not provided in Goods licensed hereunder; or

 

(e)              
a warranty or representation of the freedom to operate using the Goods.

 

    15

     

    

 

11.             
Indemnification.

 

11.1         
 Mutual Indemnification. Subject to the terms and conditions of this Agreement, including those set forth
in Section 11.2, each Party (as “Indemnifying Party”) shall indemnify, defend and hold harmless the other Party
and its officers, directors, employees, agents, Affiliates, successors and permitted assigns (collectively, “Indemnified
Party”) against any and all losses, damages, liabilities, deficiencies, claims, actions, judgments, settlements, interest,
awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys’ fees and the costs of enforcing
any right to indemnification under this Agreement and the cost of pursuing any insurance providers (collectively, “Losses”),
arising out or resulting from any third-party Claim alleging:

 

(a)              
a material breach or non-fulfillment of any representation or warranty set forth in Section 10 of this Agreement
by Indemnifying Party or Indemnifying Party’s Personnel;

 

(b)              
any grossly negligent or more culpable act or omission of Indemnifying Party or its Personnel (including any recklessness
or willful misconduct) in connection with the performance of this Agreement;

 

(c)              
any bodily injury, death of any Person or damage to real or tangible personal property caused by the willful or grossly
negligent acts or omissions of Indemnifying Party or its Personnel.

 

Notwithstanding anything to the contrary in
this Agreement, this Section 11.1 does not apply to any Claim (whether direct or indirect) for which a sole or exclusive remedy
is provided for under another section of this Agreement, including Section 4.4 or Section 10.5.

 

11.2         
Exceptions and Limitations on Indemnification. Notwithstanding anything to the contrary in this Agreement,
an Indemnifying Party is not obligated to indemnify or defend (if applicable) an Indemnified Party against any Claim if such Claim
or corresponding Losses arise out of or result from the Indemnified Party’s or its Personnel’s:

 

(a)              
gross negligence or more culpable act or omission (including recklessness or willful misconduct);

 

(b)              
bad faith failure to materially comply with any of its obligations set forth in this Agreement.

 

    16

     

    

 

11.3         
To the maximum extent permitted by applicable law, none of Bio-Techne, its directors, officers, employees, or agents
(each an “Indemnified Person”) shall have any liability or responsibility whatsoever to Buyer or any other
person or Entity for or on account of any injury, loss, or damage of any kind or nature, sustained by, or any damage assessed
or asserted against, or any other liability incurred by or imposed upon, Buyer or any other person or Entity, whether direct,
indirect, special, punitive, incidental, consequential or otherwise arising under any legal theory (and further excluding without
limitation any existing or anticipated profits or opportunities for profits lost by Buyer) arising out of or in connection with
or resulting from (i) the use or sale of the Goods by Buyer or its Affiliates; (ii) any advertising or other promotional activities
with respect to either of the foregoing; or (iii) the production, use, or sale of any product, process or service, identified,
characterized or otherwise developed by Buyer or any Affiliate with the aid or use of the Goods. Buyer shall indemnify and hold
each Indemnified Person harmless against all claims, demands, losses, damages or penalties (including, but not limited to, attorneys’
fees) made against any Indemnified Person with respect to items (i) through (iii) above, whether or not such claims are groundless
or without merit or basis. Bio- Techne shall promptly notify Buyer in writing of any claim or suit brought against Bio-Techne
in respect of which Bio-Techne intends to invoke the provisions of this Article 11. Buyer shall keep Bio-Techne informed on a
current basis of its defense of any claims pursuant to this Article 11.

 

11.4         
EXCLUSIVE REMEDY. THIS SECTION 11 SETS FORTH THE ENTIRE LIABILITY AND OBLIGATION OF EACH INDEMNIFYING PARTY
AND THE SOLE AND EXCLUSIVE REMEDY FOR EACH INDEMNIFIED PARTY FOR ANY DAMAGES COVERED BY THIS SECTION 11.

 

12.             
Intellectual Property Rights.

 

12.1         
Ownership. Buyer acknowledges and agrees that:

 

(a)              
except to the extent provided in a separate written agreement between Buyer and Bio-Techne, Bio-Techne (or its licensors)
will retain all Intellectual Property Rights used to create, embodied in, used in and otherwise relating to the Goods and any of
their component parts;

 

(b)              
any and all Bio-Techne’s Intellectual Property Rights are the sole and exclusive property of Bio-Techne or
its licensors;

 

(c)              
Buyer shall not acquire any ownership interest in any of Bio-Techne’s Intellectual Property Rights under this
Agreement;

 

(d)              
any goodwill derived from the use by Buyer of Bio-Techne’s Intellectual Property Rights inures to the benefit
of Bio-Techne or its licensors, as the case may be;

 

(e)              
if Buyer acquires any Intellectual Property Rights in or relating to any product (including any Good) purchased under
this Agreement (including any rights in any Trademarks, derivative works or patent improvements relating thereto), by operation
of law, or otherwise, such rights are deemed and are hereby irrevocably assigned to Bio- Techne or its licensors, as the case may
be, without further action by either Party; and

 

(f)               
Buyer shall use Bio-Techne’s Intellectual Property Rights only in accordance with this Agreement
and any instructions of Bio-Techne.

 

    17

     

    

 

12.2         
Prohibited Acts. Buyer shall not:

 

(a)              
 take any action that interferes with any of Bio-Techne’s rights in or
to Bio- Techne’s Intellectual Property Rights, including Bio-Techne’s ownership or exercise thereof;

 

(b)              
challenge any right, title or interest of Bio-Techne in or to Bio-Techne’s Intellectual Property Rights;

 

(c)              
make any claim or take any action adverse to Bio-Techne’s ownership of Bio-Techne’s Intellectual Property
Rights;

 

(d)              
engage in any action that tends to disparage, dilute
the value of, or reflect negatively on the products purchased under this Agreement (including Goods) or any Bio-Techne Trademark.

 

13.             
Confidentiality.

 

13.1         
Scope of Confidential Information. From time
to time during the Term, either Party (as the “Disclosing
Party”) may disclose or make available to the other Party (as the “Receiving Party”) information about
its business affairs, goods and services, Forecasts, confidential
information and materials comprising or relating to Intellectual Property Rights, trade secrets, third-party
confidential information and other sensitive or proprietary
information. Such information, as well as the terms of this Agreement, whether orally or in written, electronic or
other form or media and whether or not marked, designated
or otherwise identified as “confidential,” is collectively referred to as
 “Confidential Information” hereunder. Notwithstanding the
foregoing, Confidential Information does not include information that, at the
time of disclosure and as established by documentary evidence:

 

(a)              
is or becomes generally available to and known by the public other than as a result
of, directly or indirectly, any breach of this Section 13 by the Receiving Party or any of its Representatives;

 

(b)              
is or becomes available to the Receiving Party on a non-confidential basis from a third-party
source, provided that such third party is not and was not prohibited from disclosing such Confidential Information;

 

(c)              
was known by or in the possession of the Receiving Party or its Representatives prior
to being disclosed by or on behalf of the Disclosing Party;

 

(d)              
was or is independently developed by the Receiving Party without reference to or use
of, in whole or in part, any of the Disclosing Party’s Confidential Information; or

 

(e)              
is required to be disclosed pursuant to applicable Law.

 

    18

     

    

 

13.2         
Protection of Confidential Information. The Receiving Party shall, for two (2) years after expiry of Term:

 

(a)              
 protect and safeguard the confidentiality of the Disclosing Party’s Confidential
Information with at least the same degree of care as the Receiving Party would protect its own Confidential Information, but in
no event with less than a commercially reasonable degree of care;

 

(b)              
not use the Disclosing Party’s Confidential Information, or permit it to be accessed
or used, for any purpose other than to exercise its rights or perform its obligations under this Agreement; and

 

(c)              
not disclose any such Confidential Information to any Person, except to the Receiving
Party’s Representatives who need to know the Confidential Information to assist the Receiving Party, or act on its behalf,
to exercise its rights or perform its obligations under this Agreement.

 

The Receiving Party shall be responsible
for any breach of this Section 13 caused by any of its Representatives. On the expiration or earlier termination of this Agreement,
at the Disclosing Party’s written request, the Receiving Party and its Representatives shall, pursuant to Section 7.5(d),
promptly destroy all Confidential Information and copies thereof that it has received under this Agreement.

 

14.             
Access and Audit Rights. Buyer hereby grants Bio-Techne access to Buyer’s operations, facilities, books
and records, correspondence, writings, drawings, and receipts related to the Goods and payment of Royalties in accordance with
Section 6 for the purpose of ensuring Buyer’s compliance with the terms of this Agreement. Buyer shall maintain all pertinent
books and records for a period of [*****]. Buyer shall also cooperate fully with Bio-Techne with respect to all reasonable requests
of Bio-Techne relating to the foregoing access rights.

 

15.             
Insurance. During the Term, each Party shall, at its own expense, maintain and carry in full force and effect
commercial general liability insurance (including product liability coverage) in a sum no less than [*****] with financially sound
and reputable insurers, and upon the other Party’s request, shall provide the other Party with a certificate of insurance
evidencing the insurance coverage specified in this Section.

 

16.             
Miscellaneous.

 

16.1         
Relationship of the Parties. The relationship between Bio-Techne and Buyer is solely that of vendor and customer,
and they are independent contracting parties. Nothing in this Agreement creates any agency, joint venture, partnership or other
form of joint enterprise, employment or fiduciary relationship between the Parties. Neither Party has any express or implied right
or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any
contract, agreement or undertaking with any third party.

 

16.2         
Entire Agreement. This Agreement, including and together with the Basic Purchase Order Terms and any related
exhibits and schedules, constitutes the sole and entire agreement of the Parties with respect to the subject matter contained herein
and therein, and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written
and oral, with respect to such subject matter.

 

    19

     

    

 

16.3         
 Survival; Statute of Limitations. Subject to the limitations and other provisions of this Agreement: (a)
the representations and warranties of the Parties contained herein will survive the expiration or earlier termination of this Agreement
for a period of two (2) years after such expiration or termination; and (b) Sections 1, 10, 11, 12, and 13 of this Agreement, as
well as any other provision that, in order to give proper effect to its intent, should survive such expiration or termination,
will survive the expiration or earlier termination of this Agreement for the period specified therein, or if
nothing is specified for a period of [*****] after such expiration or termination. All other provisions of this Agreement
will not survive the expiration or earlier termination of this Agreement. Notwithstanding any right under any applicable statute
of limitations to bring a claim, no Action based upon or arising in any way out of this Agreement may be brought by either Party
after the expiration of the applicable survival or other period set forth in this Section 16.3 and the Parties waive the right
to file any such Action after the expiration of the applicable survival or other period; provided, however, that the foregoing
waiver and limitation do not apply to the collection of any amounts due to Bio-Techne under this Agreement.

 

16.4         
Notices. All notices, requests, consents, claims, demands, waivers and other communications under this Agreement
(each, a “Notice”) must be in writing and addressed to the other Party at its address set forth below (or to
such other address that the receiving Party may designate from time to time in accordance with this section). All Notices must
be delivered by personal delivery, nationally recognized overnight courier or certified or registered mail (in each case, return
receipt requested, postage prepaid). Except as otherwise provided in this Agreement, a Notice is effective only (a) on receipt
by the receiving Party, and (b) if the Party giving the Notice has complied with the requirements of this Section.

 

	Notice to Bio-Techne:	[*****]
	 	 
	Notice to Buyer:	[*****]

 

16.5          Interpretation.
For purposes of this Agreement: (a) the words “include,” “includes” and “including” are
deemed to be followed by the words “without limitation”; (b) the word “or” is not exclusive; (c) the
words “herein,” “hereof,” “hereby,” “hereto” and “hereunder”
refer to this Agreement as a whole; (d) words denoting the singular have a comparable meaning when used in the plural, and
vice-versa; and (e) words denoting any gender include all genders. Unless the context otherwise requires, references in this
Agreement: (x) to sections, exhibits, schedules, attachments and appendices mean the sections of, and exhibits, schedules,
attachments and appendices attached to, this Agreement; (y) to an agreement, instrument or other document means such
agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by
the provisions thereof; and (z) to a statute means such statute as amended from time to time and includes any
successor legislation thereto and any regulations promulgated thereunder. The Parties drafted this Agreement without regard
to any presumption or rule requiring construction or interpretation against the Party drafting an instrument or causing any
instrument to be drafted. The exhibits, schedules, attachments and appendices referred to herein are an integral part of this
Agreement to the same extent as if they were set forth verbatim herein.

 

    20

     

    

 

16.6         
Headings. The headings in this Agreement are for reference only and do not affect the interpretation of this
Agreement.

 

16.7          Severability.
If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality
or unenforceability does not affect any other term or provision of this Agreement or invalidate or render unenforceable such term
or provision in any other jurisdiction. Upon a determination that any term or provision is invalid, illegal or unenforceable,
the Parties shall negotiate in good faith to modify this Agreement to effect the original intent of the Parties as closely as
possible in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.

 

16.8         
Amendment and Modification. No amendment to this Agreement is effective unless it is in writing and signed
by an authorized Representative of each Party.

 

16.9         
Waiver.

 

(a)              
No waiver under this Agreement is effective unless it is in writing and signed by the Party waiving its right.

 

(b)              
Any waiver authorized on one occasion is effective only in that instance and only for the purpose stated, and does
not operate as a waiver on any future occasion.

 

(c)              
None of the following constitutes a waiver or estoppel of any right, remedy, power, privilege or condition arising
from this Agreement:

 

(i)              
any failure or delay in exercising any right, remedy, power or privilege or in enforcing any condition under this
Agreement; or

 

(ii)             
any act, omission or course of dealing between the Parties.

 

16.10      
Cumulative Remedies. All rights and remedies provided in this Agreement are cumulative and not exclusive,
and the exercise by either Party of any right or remedy does not preclude the exercise of any other rights or remedies that may
now or subsequently be available at law, in equity, by statute, in any other agreement between the Parties or otherwise. Notwithstanding
the previous sentence, the Parties intend that Buyer’s rights under Section 4.4, Section 4.6, Section 10.5 and each of the
Parties’ rights under Section 11 are such Party’s exclusive remedies for the events specified therein.

 

    21

     

    

 

16.11       Equitable
Remedies. Buyer acknowledges and agrees that (a) a breach or threatened breach by such Party of any of its obligations
under Section 12 would give rise to irreparable harm to the other Party for which monetary damages would not be an adequate
remedy and (b) in the event of a breach or a threatened breach by Buyer of any such obligations, Bio-Techne shall, in
addition to any and all other rights and remedies that may be available to Bio-Techne at law, at equity or otherwise in
respect of such breach, be entitled to equitable relief, including a temporary restraining order, an injunction, specific
performance and any other relief that may be available from a court of competent jurisdiction, without any requirement to
post a bond or other security, and without any requirement to prove actual damages or that monetary damages will not afford
an adequate remedy. Buyer agrees that Buyer will not oppose or otherwise challenge the appropriateness of equitable relief or
the entry by a court of competent jurisdiction of an order granting equitable relief, in either case, consistent with the
terms of this Section 16.11.

 

16.12      
Assignment. Buyer may not assign any of its rights or delegate any of its obligations under this Agreement
without the prior written consent of Bio-Techne. Bio-Techne may assign any of its rights or delegate any of its obligations to
any Affiliate or to any Person acquiring all or substantially all of Bio-Techne’s assets. Any purported assignment or delegation
in violation of this Section is null and void. No assignment or delegation relieves the assigning or delegating Party of any of
its obligations under this Agreement.

 

16.13      
Successors and Assigns. This Agreement is binding on and inures to the benefit of the Parties and their respective
permitted successors and permitted assigns.

 

16.14      
No Third-Party Beneficiaries. Except as expressly set forth in the second sentence of this Section 16.14,
this Agreement benefits solely the parties to this Agreement and their respective permitted successors and permitted assigns and
nothing in this Agreement, express or implied, confers on any other Person any legal or equitable right, benefit or remedy of any
nature whatsoever under or by reason of this Agreement.

 

16.15      
Dispute Resolution. Any dispute, controversy or claim arising out of or relating to this Agreement, or the
breach, termination or invalidity hereof (each, a “Dispute”), shall be submitted for negotiation and resolution
to the CEO of Bio-Techne (or to such other person of equivalent or superior position designated by Bio-Techne in a written Notice
to Buyer) and the CEO of Buyer (or to such other person of equivalent or superior position designated by Buyer in a written Notice
to Bio-Techne), by delivery of written Notice (each, a “Dispute Notice”) from either of the Parties to the other
Party. Such persons shall negotiate in good faith to resolve the Dispute. If the Parties are unable to resolve any Dispute within
[*****] after delivery of the applicable Dispute Notice, either Party may tile suit in a court of competent jurisdiction in accordance
with the provisions of Section 16.17 hereunder.

 

16.16      
Governing Law. This Agreement, including all exhibits, schedules, attachments and appendices attached hereto
and thereto, and all matters arising out of or relating to this Agreement, are governed by, and construed in accordance with, the
Laws of the State of Minnesota, United States of America, without regard to the conflict of laws provisions thereof. The Parties
agree that the United Nations Convention on Contracts for the International Sale of Goods does not apply to this Agreement.

 

    22

     

    

 

16.17      
Choice of Forum. In case the pre-litigation dispute resolution as set out in Article 16.15 above does not
lead to an amicable solution, any dispute, controversy or claim arising under, out of or relating to this Agreement, including
any subsequent amendments, shall be referred to and finally be settled in accordance with the Arbitration Rules of the London
Court of International Arbitration (LCIA) without recourse to the ordinary courts of law. The place of arbitration is London,
England. The number of arbitrators is three (3). The language of the arbitral proceedings is English.

 

16.18      
Counterparts. This Agreement may be executed in counterparts, each of which is deemed an original, but all
of which together are deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or
other means of electronic transmission is deemed to have the same legal effect as delivery of an original signed copy of this Agreement,
if the party sending such facsimile, e-mail or other means of electronic transmission has received express confirmation that the
recipient party received the Agreement (not merely an electronic facsimile confirmation or automatic e-mail reply).

 

16.19      
Force Majeure. Bio-Techne shall not be liable or responsible to Buyer, nor be deemed to have defaulted under
or breached this Agreement, for any failure or delay in fulfilling or performing any term of this Agreement, if such failure or
delay is caused by or results from acts beyond Bio-Techne’s control, including: (a) acts of nature; (b) flood, fire,
earthquake or explosion; (c) war, invasion, hostilities (whether war is declared or not), terrorist threats or acts, riot or other
civil unrest; (d) requirements of Law; (e) actions, embargoes or blockades in effect on or after the date of this Agreement; (I)
action by any Governmental Authority (whether or not having the effect of Law); (g) national or regional emergency; (h) strikes,
labor stoppages or slowdowns or other industrial disturbances; (i) shortages of or delays in receiving raw materials; or (j) shortage
of adequate power or transportation facilities (each, a “Force Majeure Event”).

 

    23

     

    

 

IN WITNESS WHEREOF, the Parties hereto have
executed this Agreement as of the date first set forth above.

 

	 	BIO-TECHNE CORPORATION
	 
	 	By	/s/ N. David Eansor
	 
	 	Name: N. David Eansor
	 
	 	Title: Sr, VP, Biotech Division
	 
	 	OLINK PROTEOMICS AB
	 
	 	By	/s/ Ann-Charlotte Falk
	 
	 	Name: Ann-Charlotte Falk, CEO
	 
	 	Title Olink Proteomics AB

 

    24

     

    

 

EXHIBIT A

 

SPECIFICATIONS – ANTIBODIES

 

[*****]

 

    25

     

    

 

EXHIBIT B –
PROTEINS

 

[*****]

 

    26

     

    

 

SCHEDULE 1

 

GOODS

 

[*****]

 

    27Exhibit 10.2

 

 

 

CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [****], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED
INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

 

OEM SUPPLY AGREEMENT

 

This OEM Supply Agreement (this “Agreement”)
is entered into as of December 29, 2016 (the “Effective Date”) by and between Fluidigm Corporation, a Delaware
corporation with its principal place of business at 7000 Shoreline Court, Suite 100, South San Francisco, CA 94080 (“Fluidigm”),
and Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjölds väg 52B, SE-752
37 Uppsala, Sweden (“Olink”).

 

		A	Fluidigm designs, manufactures and sells equipment incorporating integrated fluidic circuit technology,

 

		B	Olink desires to sell certain products (“Olink Products” as further defined
in Section 1.4), incorporating aspects of certain Fluidigm products (“Fluidigm Products” as further defined
in Section 1.3), and Fluidigm desires to make such Fluidigm Products available to Olink, subject to the terms and conditions
of this Agreement.

 

Therefore, the parties agree as follows:

 

1.   CERTAIN
DEFINITIONS

 

1.1            “Confidential
Information” means any proprietary information disclosed by one party to the other that is in written, graphic, machine
readable or other tangible form and is marked “Confidential” or “Proprietary” or in some other manner
to indicate its confidential nature. Confidential Information may also include oral disclosures provided that such information
is designated as confidential at the time of disclosure and reduced to a written summary by the disclosing party within [****]
after its oral disclosure, which is marked in a manner to indicate its confidential nature and delivered to the receiving party
Confidential Information will not include any information that (a) was publicly known and made generally available prior
to the time of disclosure by the disclosing party, (b) becomes publicly known and made generally available after disclosure
by the disclosing party to the receiving party through no action or inaction of the receiving party, (c) is already in the
possession of the receiving party at the time of disclosure, (d) is obtained by the receiving party from a third party without
a breach of such third party s obligations of confidentiality, or (e) is independently developed by the receiving party without
use of or reference to the disclosing party’s Confidential Information.

 

1.2            “Documentation”
means any documentation or materials provided or made available by Fluidigm to Olink under this Agreement, including documentation
and materials describing Fluidigm Products.

 

1.3            “Fluidigm
Products” [****] as described in Exhibit A. Fluidigm shall give Olink advance written notice at least [****]
before the cancellation of any Fluidigm Product. With respect to the modification of any Fluidigm Product, Fluidigm shall give
Olink updated protocols, published specifications, and all quality control reports necessary for Olink’s system validation
at least [****] for [****] and [****] for all other products listed above before the first delivery of modified Fluidigm Product.

 

1.4            “Olink
Products” means products marketed or sold by Olink that comprise a Fluidigm Product.

 

2.   GENERAL
OBLIGATIONS

 

2.1            Relationship.
Subject to the terms of this Agreement, Fluidigm agrees to sell Fluidigm Products to Olink that are identified in Exhibit A.

 

2.2            Account
Manager. Each party will designate a single point of contact within its organization to manage the relationship established
by this Agreement (“Account Manager”). Either party may change its Account Manager by providing written notice
to the other party. The Account Managers will meet as necessary to discuss the business relationship and manage the activities
contemplated by this Agreement. Disputes that cannot be resolved by the Account Managers will be escalated to more senior executives
for resolution.

 

2.3            Advertising
and Marketing Practices. In advertising and marketing of Fluidigm Products and otherwise performing under this Agreement,
Olink will: (a) not engage in any deceptive, misleading, illegal, or unethical practices; (b) not make any representations,
warranties, or guarantees concerning the Fluidigm Products that are inconsistent with or in addition to those made by Fluidigm
in this Agreement; and (c) comply with all applicable federal, state, and local laws and regulations. Olink will indemnify,
defend, and hold Fluidigm harmless from and against all damages, liabilities, costs, and expenses, including attorneys’
and experts fees and expenses, that Fluidigm may incur as the result of any action brought against Fluidigm and arising out of
the acts of Olink or its agents in breach of this Section 1.1.

 

    -1-

     

    

 

2.4            Training.
Olink will ensure that its employee sales representatives receive appropriate training relating to the Olink Products, and document
who has received such training and the date such training was provided.

 

2.5            Proprietary
Rights. Title to and ownership of all intellectual property rights embodied by the Fluidigm Products, including all related
technical know-how, are and as between the parties will remain the exclusive property of Fluidigm and its suppliers. Olink will
not reverse engineer, disassemble, or otherwise attempt to reconstruct, identify or discover any underlying ideas, techniques
or functionalities of the Fluidigm Products. [****].

 

2.6            Export
Restrictions. Olink will obtain all necessary permits and licenses as may be required by, and conforming with, all applicable
laws and regulations poor to making the Olink Products available, and all laws, rules and regulations as they pertain to
the responsibility to sell Olink Products. Olink represents and warrants that Olink is not located in, under the control of. or
a national or resident of any country on the United States Commerce Department’s Table of Denial Orders.

 

2.7            Regulatory
Compliance. Olink shall be solely responsible for obtaining and maintaining all necessary and required regulatory clearances,
approvals and licenses from all applicable regulatory agencies to commercialize and distribute the Olink Products including any
required medical device clearances, approvals and licenses Olink shall comply with all applicable laws and regulations. During
the Term, Olink shall be solely responsible for performing any required recall or market withdraw of the Olink Products. Olink
shall keep a record of all written and oral complaints concerning the Olink Products. Olink shall promptly inform Fluidigm of
all known Fluidigm Product defects, safety problems or any information associated with the safety of the Fluidigm Products and
shall promptly notify Fluidigm in writing of any third party dispute involving a Fluidigm Product.

 

2.8            Quality.
Subject to Section 10, Olink shall be solely responsible for responding to, and addressing all, customer complaints related
to the Olink Products. Olink shall promptly forward to Fluidigm all customer complaints related directly to the quality or performance
of the Fluidigm Products.

 

2.9            Direct
Sales by Fluidigm. Fluidigm reserves the unrestricted right to market, and sell Fluidigm Products worldwide, including without
limitation through distributors, resellers, and other third party intermediaries and directly to any customer.

 

3.   PURCHASE
OF FLUIDIGM PRODUCTS

 

3.1            Purchase
Orders. The purchase and sale of Fluidigm Products will be made against specific written purchase orders submitted by Olink
to Fluidigm or to any Fluidigm distributor pursuant to Fluidigm s written instructions. All purchase orders shall contain the
information set forth in Exhibit B attached hereto. If Olink is in compliance with Section 5.1 at the time it submits
a purchase order, Fluidigm or the Fluidigm distributor shall accept all such binding purchase orders made pursuant to Section 3.6.
Fluidigm or the Fluidigm distributor will notify Olink of acceptance within 14 days of receipt. Accepted purchase orders are non-cancelable.
In the event that a Fluidigm distributor accepts a purchase order on behalf of Fluidigm, Fluidigm shall ensure such distributor’s
compliance with the terms of this Agreement.

 

3.2            Fluidigm
Product Pricing. The purchase price for each Fluidigm Product is set forth in Exhibit A. Fluidigm may revise the
pricing set forth in Exhibit A at any time by providing [****] prior written notice, such price revisions will occur
no more than [****]. Such revised prices will apply to all purchase orders received after [****] following notice of the revision.
Prices do not include any taxes, customs charges, duties, or transportation, rigging, drayage, insurance charges or any other
costs associated with Fluidigm’s delivery to Olink’s specified location.

 

3.3            Delivery,
Acceptance and Title. Unless otherwise expressly agreed to in writing by Fluidigm, all deliveries to destinations within the
United States are [****], and all deliveries to destinations outside the U.S. are [****]. Fluidigm’s title (except for software,
which is only licensed), and all risk of loss, passes to Olink, and Fluidigm’s liability as to delivery ceases, [****].
For avoidance of doubt, if the above-identified shipping terms are deemed not to apply, title and risk of loss shall pass to Olink
upon [****] unless both parties agree in advance and in writing otherwise. Unless specific shipping instructions have been agreed
to in writing between Fluidigm and Olink, Fluidigm will ship in accordance with its standard practices and In compliance with
all applicable laws and regulations. For multiple unit and/or multiple Fluidigm Product orders, Fluidigm may make delivery in
installments, and each installment shall be deemed to be a separate sale. Fluidigm may issue a separate invoice for each installment,
which invoice shall be paid without regard to prior or subsequent installments. Subject to the terms and conditions herein, all
Products shall be conclusively and irrevocably deemed accepted without qualification by Olink upon delivery. Olink, however, will
notify Fluidigm or its representative in writing of any nonconformity to Fluidigm’s extant specifications promptly after
delivery. Fluidigm shall be entitled to repair or replace damaged, missing or nonconforming Fluidigm Products, and, subject to
the indemnification obligations in section 10, such repair or replacement shall constitute Clink’s sole and exclusive remedies,
and Fluidigm’s sole liability and obligation, for any damaged, missing or nonconforming Fluidigm Products.

 

    -2-

     

    

 

3.4            Instrument
Inspection. Without limiting the preceding section, within [****] of receipt, Olink shall promptly uncrate and visually inspect
any Fluidigm Product upon receipt and notify Fluidigm in writing of receipt of the Fluidigm Product and any visual damage or missing
parts that Olink notes. If Olink fails to comply with this section, Olink shall be deemed to have waived its rights to claim incorrect
or incomplete delivery or packaging and any related warranty rights.

 

3.5            Recalls.
If Fluidigm decides to recall, replace or take other action with respect to any Fluidigm Products, it will promptly notify Olink
and Olink will immediately cease distribution of any units of Olink Product incorporating such Fluidigm Products in its possession
or control, which are subject to the action until the course of action to be taken has been determined. Olink will maintain traceability
record to ensure that each Fluidigm Product can be located at an end-user customer site. In the event Fluidigm initiates a voluntary
or mandatory recall of Fluidigm Product, Fluidigm will be responsible for bringing its products into compliance with appropriate
regulatory statutes and will bear costs necessary to do so.

 

3.6            Forecasts.
At least [****] before the start of each calendar quarter during the Term. Olink will provide Fluidigm with a written, [****]
forecast in good faith its anticipated Fluidigm Product needs for the upcoming [****]. The forecast for the immediately upcoming
[****] will be binding on Olink and Olink shall submit purchase orders in amount not less than the binding portion of the forecast[****].

 

3.7            Pricing.
Olink will set the price for its resale of Olink Products to Olink customers (“Customers”) at its sole discretion
and may offer the Olink Products in connection with other Olink services or products for a single price.

 

4.   SUPPORT

 

4.1            INTENTIONALLY
OMITTED

 

5.   PAYMENT
TERMS AND REPORTING

 

5.1            Payment
Terms. Unless otherwise expressly agreed to in writing by Fluidigm, Fluidigm shall invoice Olink for Fluidigm Products ordered
by Olink upon shipment of the Fluidigm Product and such invoice shall cover Olink’s purchase price for the Fluidigm Product
and any freight, insurance, Taxes and Olink shall pay all such amounts. Unless otherwise expressly agreed to in writing by Fluidigm,
all invoices shall be issued and payable in U.S. Dollars, and are due and payable [****] from date of invoice, subject to credit
approval. Each delivery shall be considered a separate and independent transaction and payment therefor made accordingly. Amounts
outstanding [****] from the date of invoice shall be subject to a service charge of [****], or the maximum allowed by applicable
law, if less. If Olink fails to make any payment when due or if Fluidigm deems Olink to be or to have become un-creditworthy,
then, without prejudice to Fluidigm’s rights. Fluidigm may, at its option, cancel or suspend future deliveries, and/or require
prepayment, letter of credit, or other payment method(s).

 

5.2            Security
Interest. Fluidigm hereby reserves a purchase money security interest in Fluidigm Products sold and the proceeds thereof,
in the amount of its purchase price. In the event of default by Olink of any of its obligations to Fluidigm, Fluidigm will have
the right to repossess the Fluidigm Products sold hereunder without liability to Olink, and Olink will assemble the Fluidigm Products
so that Fluidigm may repossess them without a breach of the peace. These security interests will be satisfied by payment in full.
A copy of the invoice may be filed with appropriate authorities at any time as a financing statement and/or chattel mortgage,
in order to perfect Fluidigm’s security interest. On request of Fluidigm, Olink will execute financing statements and other
instruments Fluidigm may request to perfect its security interest.

 

5.3            Taxes.
Each Party shall be responsible for the payment of its own tax liabilities arising from this Agreement’s transaction. All
transfer documentary, sales, use, stamp, registration, value added and other such Taxes and fees (including any penalties and
interest) incurred in connection with this Agreement shall be borne and paid by respective party when due.

 

6.   TERM
AND TERMINATION

 

6.1            Term.
This Agreement will commence upon the Effective Date and continue for five (5) years (“Initial Term”),
unless earlier terminated in accordance with the provisions of this Agreement. This Agreement will automatically renew for additional
successive twelve (12)-month terms unless at least ninety (90) days before the end of the then-current term either party provides
written notice to the other party that it does not want to renew. After the first thirty (30) months of the Initial Term.
Fluidigm shall also have the option, in sole and absolute discretion, to terminate this Agreement in the event Olink purchases
less than eighty percent (80%) of the amounts set forth in the binding forecasts provided by Olink pursuant to Section 3.6
for three consecutive calendar quarters.

 

    -3-

     

    

 

6.2            Suspension:
Termination for Cause. Fluidigm may immediately suspend provision of Fluidigm Products if Olink fails to make any payment
to Fluidigm within [****] of the receipt of the associated invoice. If either party fails to perform any of its material obligations
under this Agreement, including payment in accordance with Section 6, the other party may terminate this Agreement by giving
[****] prior written notice, provided that the matters set forth in such notice are not cured to the other party’s reasonable
satisfaction within the [****]. If either party commits or suffers (voluntarily or involuntarily) an act of bankruptcy, receivership,
liquidation, or similar event, the other party may immediately terminate this Agreement.

 

6.3            Termination
for Provider Failure. Fluidigm may terminate this Agreement [****] after the provision of written notice to Olink if any third
party provider upon which Fluidigm relies in a material respect to manufacture the Fluidigm Products ceases to perform on Fluidigm’s
behalf for any reason and Fluidigm is not able to procure the third party provider’s products or services from another party
on similar terms to those with the original third party supplier. If Fluidigm terminates this Agreement under Section 6.3,
then Fluidigm shall give Olink the right to purchase its pro rata basis of any remaining Fluidigm Products in Fluidigm s inventory
at the then-current price

 

6.4            No
Liability for Termination. Except as expressly required by law, in the event of termination of this Agreement by either party
in accordance with any of the provisions of this Agreement, neither party will be liable to the other, because of such termination,
for compensation, reimbursement, or damages on account of the loss of prospective profits or anticipated sales or on account of
expenditures, inventory, investments, leases, or commitments in connection with the business or goodwill of Fluidigm or Olink.
Termination will not. however, relieve either party of obligations incurred prior to the effective date of the termination.

 

6.5            Effects
of Termination

 

(a)            In
addition the following provisions will survive any expiration or termination of this Agreement: Sections 5, 6.4, 6.5, 8, 9, 10,
11, 12, and 13, The termination or expiration of this Agreement will not relieve Olink of the obligation to pay any fees that are
due to Fluidigm under this Agreement

 

7.   TRADEMARK
USAGE

 

7.1            Use
of Company Names. Fluidigm may identify Olink in Fluidigm advertising and marketing materials provided that such materials
are approved in writing in advance by Olink, such approval not to be unreasonably withheld. Olink may identify Fluidigm as the
supplier Of the Fluidigm Products in Olink s advertising and marketing materials provided that such materials are approved in
writing in advance by Fluidigm, such approval not to be unreasonably withheld.

 

8.   LIMITED
WARRANTIES AND DISCLAIMER

 

8.1            Limited
Warranty to Olink. Fluidigm warrants to and only to Olink that for [****] from the date of shipping (“Instrument
Warranty Period”) that the Fluidigm Products shall be free from defects in design, material and workmanship,
and conform to Fluidigm’s published specifications at the time of purchase in all material respects Clink’s sole and
exclusive remedy and Fluidigm’s sole and exclusive liability, under the foregoing warranty shall be for Fluidigm to repair
or replace, as determined by Fluidigm in its reasonable discretion, such Fluidigm Products. Nonconforming Fluidigm Products will
be serviced al Clink’s facility or, at Fluidigm’s option, Fluidigm’s facility. If service is performed at Fluidigm’s
facility. Fluidigm will bear shipping costs including insurance and risk of loss. This limited warranty is subject to certain
exceptions listed below

 

8.2            Exceptions.
These warranties shall not apply to and shall be void for any Fluidigm Product that (i) was subject to improper or abnormal
use, storage, or operating environment, or any abuse, neglect, negligence or accident, including without limitation Olink’s
failure to properly perform routine maintenance and maintain the Fluidigm Product site in accordance with Fluidigm’s written
requirements or the use of the Fluidigm Product with any non-Fluidigm product (except as may be specifically recommended, with
respect to standard laboratory reagents, tools and equipment ancillary to use of the Fluidigm Product, in the then-current documentation
for that Fluidigm Product), (ii) has been incorrectly installed at an end users facility by any person other the Fluidigm
or its authorized representative, (iii) repaired, altered, disassembled or reassembled, or moved within, or removed from,
Olink’s facility by persons other than Fluidigm or its, (iv) has failed due to externally caused short circuits, incorrect
voltages, failure or fluctuation of electrical power, lightning, static or other improper external inputs, or due to Force Majeure,
or (v) used with any item other than Fluidigm Products (except as may be set forth in the extant applicable Fluidigm protocol
for use of a Fluidigm Product, with associated standard laboratory tools and equipment ancillary to use of such Product). For
example, use of an Olink Product with [****] voids the warranty for that reader, unless specifically authorized in writing by
Fluidigm. Olink acknowledges that failure to comply with any restriction of use set forth herein will invalidate any warranty
provided herein for the reader used in a non-compliant manner. For clarity, and without limitation, use of an Fluidigm Product
with consumables other than the Consumables specified for use with that Fluidigm Product will void the warranty for that Fluidigm
Product. Without limiting the foregoing, with regard to software, these warranties shall not apply to any failure to conform that
is caused by the use or operation of the software in an environment other than that intended or recommended by Fluidigm, or modifications
to the software not made or authorized by Fluidigm. Except for assignments in accordance with section 13.2. These warranties are
not transferable or assignable, including without limitation, in any re-sale of a Fluidigm Product, and any such attempt to transfer
or assign these warranties shall be void Fluidigm neither assumes, nor authorizes any other person to assume for it, any other
obligations or liabilities in connection with the sale of Fluidigm Products. Repair or replacement of a Fluidigm Product shall
not extend the original warranty period for that Fluidigm Product Except as detailed in section 8.1. Fluidigm s warranties do
not cover de-installation, re-installation, or transportation of Fluidigm Products.

 

    -4-

     

    

 

8.3            WARRANTY
DISCLAIMER. EXCEPT FOR THE EXPRESS WARRANTY PROVIDED TO OLINK UNDER SECTION 8 1. FLUIDIGM MAKES NO ADDITIONAL REPRESENTATION
OR WARRANTY OF ANY KIND WHETHER EXPRESS, IMPLIED (EITHER IN FACT OR BY OPERATION OF LAW), OR STATUTORY, AS TO ANY MATTER
WHATSOEVER FLUIDIGM EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY. FITNESS FOR A PARTICULAR PURPOSE, QUALITY AND
ACCURACY. FLUIDIGM DOES NOT WARRANT AGAINST INTERFERENCE WITH ENJOYMENT OR AGAINST INFRINGEMENT EXCEPT AS PROVIDED IN SECTION 9.
OLINK WILL NOT HAVE THE RIGHT TO MAKE OR PASS ON ANY REPRESENTATION OR WARRANTY ON BEHALF OF FLUIDIGM TO ANY CUSTOMER OR OTHER
THIRD PARTY EXCEPT THAT OLINK MAY PASS ON ANY REPRESENTATION AND WARRANTY TO THE EXTENT NOT INCONSISTENT WITH THIS AGREEMENT

 

8.4            Warranties.
Olink warrants to Fluidigm that its entry into this Agreement is rightful and does not violate any other agreement to which it
is a party, and its conduct in performing its obligations under this Agreement will conform to all applicable laws, treaties and
international agreements; general and local industry standards, rules and regulations; and good commercial practices. Fluidigm
warrants to Olink that its entry into this Agreement is rightful and does not violate any other agreement to which it is a party,
and its conduct In performing its obligations under this Agreement will conform to all applicable laws, treaties and international
agreements; general and local industry standards, rules and regulations; and good commercial practices

 

9.   INTELLECTUAL
PROPERTY INFRINGEMENT

 

9.1            Infringement
Defense. Fluidigm will indemnify, defend and hold harmless Olink and its employees, directors, agents, and representatives
(“Olink Indemnified Parties”) from any actual or threatened third party claim that the Fluidigm Products as
provided by Fluidigm directly infringe or misappropriate any patent, copyright or trade secret right of any third party if: (a) the
applicable Olink Indemnified Party gives Fluidigm written notice of the claim within 30 days of its filing, (b) Fluidigm
has full and complete control and responsibility over the defense and associated costs of defense including attorneys’ fees
and with respect to accused Fluidigm components, settlement of the claim, (c) the applicable Olink Indemnified Party provides
assistance in connection with the defense and settlement of the claim as Fluidigm may reasonably request, and (d) the applicable
Olink Indemnified Party complies with any settlement or court order mads in connection with the claim (e.g. relating to the future
use of any infringing materials).

 

9.2            Infringement
Indemnification. Fluidigm will indemnify each of the Olink Indemnified Parties against (a) all damages, costs and attorneys’
fees finally awarded against any of them in any proceeding under Section 91; (b) all out-of-pocket costs (including
reasonable attorneys’ fees) reasonably incurred by any of them in connection with the defense of such proceeding (other
than attorneys’ fees and costs incurred without Fluidigm’s consent after Fluidigm has accepted defense of such claim);
and (c) if any proceeding arising under Section 9.1 is settled, ail amounts to any third party agreed to by Fluidigm
in settlement of any such claims.

 

9.3            Mitigation
of Infringement Action. If any Fluidigm Product becomes, or in Fluidigm’s reasonable opinion is likely to become, subject
of a claim of infringement of any third party under Section 9.1, then Fluidigm will either: (a) procure the continuing
right of Olink to sell the Fluidigm Products; (b) replace or modify the Fluidigm Products in a functionally equivalent manner
so that it no longer infringes; or if, despite its commercially reasonable efforts, Fluidigm is unable to do either (a) or
(b), Fluidigm may (c) terminate this Agreement with respect to such Fluidigm Product only.

 

    -5-

     

    

 

 

9.4            Exclusions.
Fluidigm will have no obligation under this Section 9 for any infringement to the extent that it arises out of or is based
upon: (a) the combination, operation or use of the Fluidigm Products with any other product or service if such infringement
would have been avoided but for such combination, operation, or use; (b) designs, requirements, or specifications for the
Fluidigm Products required by or provided by Olink, if the alleged infringement would not have occurred but for such designs,
requirements, or specifications; (c) sale of the Fluidigm Products outside of the scope of this Agreement; or (d) Olink’s
failure to comply with instructions provided by Fluidigm, if the alleged infringement would not have occurred but for such failure
(collectively, the “Excluded Causes”).

 

9.5            Exclusive
Remedy. This Section 9 states Fluidigm’s sole and exclusive liability, and the Olink indemnified Parties’
sole and exclusive remedy, for the actual or alleged infringement of any third party intellectual property right by the Fluidigm
Products or Olink’s marketing or sale of the Fluidigm Products.

 

10.  INDEMNIFICATION

 

10.1          Olink
Indemnification. Olink will indemnify, defend and hold Fluidigm and its affiliates and their employees, directors, agents,
and representatives (“Fluidigm Indemnified Parties”) harmless from any actual or threatened third party claim
arising out of or based upon the Excluded Causes. Olink’s performance or failure to perform under this Agreement, Olink’s
failure to comply with applicable laws and regulations; or Olink’s negligence or willful misconduct, if: (a) the applicable
Fluidigm Indemnified Party gives Olink prompt written notice of the claim; (b) Olink has full and complete control over the
defense and settlement of the claim; (c) the applicable Fluidigm Indemnified Party provides assistance in connection with
the defense and settlement of the claim as Olink may reasonably request; and (d) the applicable Fluidigm Indemnified Party
complies with any settlement or court order made in connection with the claim (e.g., relating to the future use of any infringing
materials).

 

10.2          Fluidigm
Indemnification. Fluidigm will indemnify, defend, and hold harmless Olink (“Olink Indemnified Party”) from
any actual or threatened third party claim arising out of or based upon (a) any breach by Fluidigm of this Agreement, including
any representations and warranties herein; (b) any failure of Fluidigm to perform or any breach by Fluidigm of any of its
covenants or obligations contained in this Agreement or Fluidigm’s negligence or willful misconduct, (c) any failure
of Fluidigm to comply with applicable laws and regulation; and; (d) the use, export, import, manufacture, or exploitation
of Fluidigm Products if: (a) the applicable Olink Indemnified Party gives Fluidigm prompt written notice of the claim; (b) Fluidigm
has full and complete control over the defense and settlement of the claim; (c) the applicable Olink Indemnified Party provides
assistance in connection with the defense and settlement of the claim as Fluidigm may reasonably request; and (d) the applicable
Olink Indemnified Party complies with any settlement or court order made in connection with the claim (e.g., relating to the future
use of any infringing materials).

 

10.3          Indemnification.
As described in Sections 10.1 and 10.2, an indemnifying Party will indemnify each of the Indemnified Parties against (a) all
damages, costs, and attorneys’ fees finally awarded against any of them in any proceeding under Section 10.1 or 10.2;
(b) all out-of- pocket costs (including reasonable attorneys’ fees) reasonably incurred by any of them in connection
with the defense of such proceeding (other than attorneys’ fees and costs incurred without the indemnifying Party’s
consent after the indemnifying Party has accepted defense of such claim); and, (c) if any proceeding arising under Section 10.1
or 10.2 is settled, the indemnifying Party will pay any amounts to any third party agreed to by the indemnifying Party in settlement
of any such claims. Each party agrees to maintain appropriate insurance to cover such party’s respective risks and liabilities
under this Agreement with coverage amounts commensurate with such risks and liabilities, taking into account each party’s
capability for self-insurance.

 

10.4          Exclusions.
Olink will have no obligation under this Section 10 to the extent that Fluidigm is obligated under Section 9.1 to defend
Olink against such third party claim. Fluidigm will reimburse Olink for costs or damages that result from any such actions in
accordance with Section 10.

 

11.  CONFIDENTIAL
INFORMATION

 

11.1          Non-Use
and Non-Disclosure. Each party will (a) treat as confidential all Confidential Information of the other party, (b) not
disclose such Confidential Information to any third party, except on a “need to know” basis to third parties that
have signed a non-disclosure agreement containing provisions substantially as protective as the terms of this Section, provided
that the disclosing party has obtained the written consent to such disclosure from the other party, and (c) will not use
such Confidential Information except in connection with performing its obligations or exercising its rights under this Agreement.
Each party is permitted to disclose the other party’s Confidential Information if required by law so long as the other party
is given prompt written notice of such requirement prior to disclosure and assistance in obtaining an order protecting such information
from public disclosure.

 

    -6-

     

    

 

11.2          Confidentiality
of Agreement. Neither party to this Agreement will disclose the terms of this Agreement to any third party without the consent
of the other party, except as required by securities or other applicable laws. Notwithstanding the above provisions, each party
may disclose the terms of this Agreement (a) in connection with the requirements of a public offering or securities filing,
(b) in confidence, to accountants, banks, and financing sources and their advisors, (c) in confidence, in connection
with the enforcement of this Agreement or rights under this Agreement, or (d) in confidence, in connection with a merger
or acquisition or proposed merger or acquisition, or the like.

 

12.  LIMITATION
OF LIABILITY

 

12.1          DISCLAIMER
OF CONSEQUENTIAL DAMAGES. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT, NEITHER PARTY WILL NOT, UNDER
ANY CIRCUMSTANCES, BE LIABLE TO THE OTHER PARTY OR ANY CUSTOMER FOR CONSEQUENTIAL, INCIDENTAL. SPECIAL, PUNITIVE, OR EXEMPLARY
DAMAGES ARISING OUT OF OR RELATED TO THE TRANSACTION CONTEMPLATED UNDER THIS AGREEMENT INCLUDING BUT NOT LIMITED TO LOST PROFITS
OR LOSS OF BUSINESS, EVEN IF THE PARTY IS APPRISED OF THE LIKELIHOOD OF SUCH DAMAGES OCCURRING.

 

12.2          CAP
ON LIABILITY. EXCEPT FOR EACH PARTY’S INDEMNIFICATION OBLIGATIONS, UNDER NO CIRCUMSTANCES WILL EITHER PARTY’S
TOTAL LIABILITY OF ALL KINDS ARISING OUT OF OR RELATED TO THIS AGREEMENT (INCLUDING BUT NOT LIMITED TO WARRANTY CLAIMS), REGARDLESS
OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR OTHERWISE, EXCEED THE TOTAL AMOUNT PAID
BY OLINK TO FLUIDIGM UNDER THIS AGREEMENT [****].

 

12.3          INDEPENDENT
ALLOCATIONS OF RISK. EACH PROVISION OF THIS AGREEMENT THAT PROVIDES FOR A LIMITATION OF LIABILITY, DISCLAIMER OF WARRANTIES,
OR EXCLUSION OF DAMAGES IS TO ALLOCATE THE RISKS OF THIS AGREEMENT BETWEEN THE PARTIES. THIS ALLOCATION IS REFLECTED IN THE PRICING
OFFERED BY FLUIDIGM TO OLINK AND IS AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN BETWEEN THE PARTIES. EACH OF THESE PROVISIONS
IS SEVERABLE AND INDEPENDENT OF ALL OTHER PROVISIONS OF THIS AGREEMENT, AND EACH OF THESE PROVISIONS WILL APPLY EVEN IF THE WARRANTIES
IN THIS AGREEMENT HAVE FAILED OF THEIR ESSENTIAL PURPOSE.

 

13.  GENERAL

 

13.1          Independent
Contractors. The relationship of the parties established by this Agreement is that of independent contractors, and nothing
contained in this Agreement should be construed to give either party the power to (a) act as an agent or (b) direct
or control the day-to- day activities of the other. Financial and other obligations associated with each party’s business
are the sole responsibility of that party.

 

Nothing in this Agreement will create a
joint venture, joint enterprise or partnership, or any relationship other than that of independent contractors, which is the only
relationship intended by the parties

 

13.2          Non-Assignability
and Binding Effect. Neither Party may assign its rights and obligations under this Agreement without the written consent of
the other Party, except pursuant to a merger acquisition, or sale of all or substantially all of its assets. Subject to the foregoing,
this Agreement will be tending upon and inure to the benefit of the parties and their successors and assigns.

 

13.3          Notices.
Any notice required or permitted to be given under this Agreement will be effective if it is in writing and sent by certified
or registered mail, or insured courier return receipt requested, to the appropriate party at the address set forth above and with
the appropriate postage affixed. Either party may change its address for receipt of notice by notice to the other party in accordance
with this section. Notices are deemed given two business days following the date of mailing or one business day following delivery
to a courier.

 

13.4          Force
Majeure. Nonperformance of either party will be excused to the extent that performance is rendered impossible by strike, fire
flood, governmental acts, orders or restrictions, or any other reason where failure to perform is beyond the control and not caused
by the negligence of the non-performing party.

 

13.5          Foreign
Corrupt Practices Act. In conformity with the United States Foreign Corrupt Practices Act and with Fluidigm’s corporate
policies regarding foreign business practices as disclosed to Olink. Olink and its employees and agents will not directly or indirectly
make and offer payment, promise to pay, or authorize payment, or offer a gift, promise to give, or authorize the giving of anything
of value for the purpose of influencing an act or decision of an official of any government (including a decision not to act)
or inducing such a person to use his influence to affect any such governmental act or decision in order to assist Fluidigm in
obtaining, retaining, or directing any such business.

 

    -7-

     

    

 

13.6          Governing
Law and Arbitration. This Agreement and any disputes arising out of or relating do this Agreement (including its formation
or termination) or Fluidigm’s goods software or related services (“Disputes”) shall be governed by and
interpreted in accordance with the laws of the State of New York, U.S.A. excluding choice of law provisions and excluding the
United Nations Convention on Contracts for the International Sale of Goods. Fluidigm and Olink agree that any dispute or controversy
arising out of or in connection with this Agreement shall be finally settled by binding arbitration under the extant rules of
the International Centre for Dispute Resolution, by one (1) arbitrator appointed in accordance with such rules. The venue
of any such arbitration shall be New York. The arbitration shall be conducted in English, and any written evidence originally
in a language other than English shall be submitted in English translation accompanied by the original or a true copy thereof.
The decision and/or award rendered by the arbitrator shall be written, final and non-appealable, and the parties agree that the
decision and award of the arbitrator shall be the sole exclusive and binding remedy between them regarding any and all disputes
controversies, claims and counterclaims property before the arbitrator. The parties agree that, any provision of applicable law
notwithstanding, they will not request, and the arbitrator shall have no authority to award, punitive or exemplary damages against
any party The costs of any arbitration, including administrative fees and fees of the arbitrator, shall be shared equally by the
parties, and each party shall bear the cost of its own attorneys’ and expert fees, provided that the arbitrator may at his
or her discretion award to the prevailing party the costs and expenses incurred by the prevailing party in connection with the
arbitration proceeding. The decision and/or award of the arbitrator may be entered m any court of competent jurisdiction for a
judicial recognition of the decision and applicable orders of enforcement (which may include, without limitation, permanent injunctive
relief or orders for specific performance or for equitable relief), and either party may apply to any court of competent jurisdiction
for appropriate restraining orders or temporary injunctive relief pending resolution of any arbitration proceeding. For avoidance
of doubt, any such equitable remedies shall be cumulative and not exclusive and are in addition to any other remedies which either
party may have under this Agreement or applicable law.

 

13.7          Remedies
Cumulative. The remedies provided to the parties under this Agreement are cumulative and will not exclude any other remedies
to which a party may be lawfully entitled.

 

13.8         Waiver
and Severability. The waiver by either party of any breach of this Agreement does not waive any other breach. The failure
of any party to insist on strict performance of any covenant or obligation under this Agreement will not be a waiver of such party
s right to demand strict compliance in the future, nor will the same be construed as a novation of this Agreement If any part
of this Agreement is unenforceable, the remaining portions of this Agreement will remain in full force and effect.

 

13.9          Drafting
and Interpretation. The parties have had an equal opportunity to participate in the drafting of this Agreement and the attached
Exhibits. No ambiguity will be construed against any party based upon a claim that that party drafted the ambiguous language.
The headings appearing at the beginning of several sections contained in this Agreement have been inserted for identification
and reference purposes only and must not be used to construe or interpret this Agreement. Whenever required by context a singular
number will include the plural the plural number will include the singular, and the gender of any pronoun will include all genders.

 

13.10        Entire
Agreement. This Agreement, including any Exhibits, is the final and complete expression of all agreements between these parties
and supersedes all previous oral and written agreements regarding these matters. It may be changed only by a written agreement
signed by the party against whom enforcement is sought. The Exhibits referred to in this Agreement are incorporated by this reference
as if fully set forth here.

 

13.11        Execution
in Counterparts and by Facsimile. This Agreement may be executed in counterparts, each of which will be deemed an original,
but all of which taken together will constitute but one and the same instrument. The Agreement may be executed and delivered electronically
by facsimile or PDF and the parties agree that such facsimile or PDF execution and delivery will have the same force and effect
as delivery of an original document with original signatures, and that each party may use such facsimile or PDF signatures as
evidence of the execution and delivery of this Agreement by all parties to the same extent that an original signature could be
used.

 

13.12        Language.
This Agreement is in the English language only, which language will be controlling m all respects, and ail versions hereof in
any other language will not be binding on the parties. All communications and notices to be made or given pursuant to this Agreement
will be in the English language.

 

    -8-

     

    

 

	For Fluidigm Corporation	 	For Olink Proteomics AB
	 	 	 
	Name:	Steve McPaail	 	Name:	Lotta Falk, CEO
	Title:	CCO	 	Title:	Olink Proteomics AM
	Signature:	/s/ Steve McPaail	 	Signature:	/s/ Lotta Falk
	Date:	29 Dec. 2016	 	Date:	Dec. 23, 2016

 

     - 9 -

     

    

 

EXHIBIT A

 

FLUIDIGM PRODUCTS, STRATEGIC PRICING
AND NON-BINDING INDICATIONS OF POTENTIAL FUTURE ANNUAL VOLUMES

 

[****]

 

     

     

    

 

EXHIBIT B

 

PURCHASE ORDER REQUIREMENTS

 

[****]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]